BCM
BIO icon

Breithorn Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Breithorn Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,800
Closed -$257K – 44
2016
Q2 		$257K Hold
1,800
– – 0.2% 43
2016
Q1 		$246K Hold
1,800
– – 0.17% 47
2015
Q4 		$250K Hold
1,800
– – 0.17% 45
2015
Q3 		$242K Hold
1,800
– – 0.17% 39
2015
Q2 		$271K Hold
1,800
– – 0.17% 41
2015
Q1 		$243K Hold
1,800
– – 0.15% 43
2014
Q4 		$217K Sell
1,800
-30,420
-94% -$3.5M 0.14% 45
2014
Q3 		$3.65M Sell
32,220
-16,400
-34% -$1.94M 2.38% 23
2014
Q2 		$5.82M Sell
48,620
-310
-0.6% -$37.9K 3.62% 12
2014
Q1 		$6.27M Sell
48,930
-1,220
-2% -$156K 3.33% 11
2013
Q4 		$6.2M Buy
50,150
+2,950
+6% +$359K 3.47% 9
2013
Q3 		$5.55M Buy
47,200
+260
+0.6% +$30.7K 3.24% 8
2013
Q2 		$5.27M Buy
+46,940
New +$5.51M 3.48% 6

Other funds holding BIO

ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CM
Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Breithorn Capital Management's BIO Position: Q3 2016 in Review

Breithorn Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2016, closing a stake of 1,800 shares — an estimated $257K sold.

Breithorn Capital Management first reported a position in BIO in Q2 2013 and held it in 13 quarters. The position peaked at $6.27M in Q1 2014. 242 funds tracked by Wall St. Rank hold BIO as of Q3 2016.

  • Breithorn Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2016 after selling out during the quarter.
  • Breithorn Capital Management sold 1,800 Bio-Rad Laboratories Class A shares in Q3 2016, an estimated $257K.
  • Breithorn Capital Management first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 13 quarters.
  • Breithorn Capital Management's Bio-Rad Laboratories Class A position peaked at $6.27M in Q1 2014.
  • 242 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2016.

Based on Breithorn Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.